ArticleMolecular & cellular proteomics : MCP2026
High Accuracy Stool Biomarkers of Precancerous Colorectal Cancer Identified Using a 2000-Plex Immunoproteomic Screen.
Article in Molecular & cellular proteomics : MCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the morbidity and mortality associated with colorectal cancer (CRC), novel biomarkers are clearly warranted, especially for early detection. An antibody-based screen of 2000 proteins was utilized to identify stool proteins that were elevated in patients with CRC, compared with healthy controls (HCs). Thirty-seven lead candidates were selected for ELISA validation in three independent cohorts comprised of CRC patients, advanced adenoma patients, and HCs, drawn from two different ethnicities. Of the 2000 proteins interrogated, 116 were differentially expressed in CRC stool, with 45 being elevated at twofold or higher; 37 of these proteins were selected for ELISA validation in three independent patient cohorts. Stool matrix metalloproteinase (MMP)-8, MMP-9, hemoglobin, Peptidoglycan Recognition Protein-S (PGRP-S), haptoglobin, and fibrinogen emerged as being most discriminatory for distinguishing CRC from HCs (area under the curve, 0.91-0.95), across cohorts and ethnicities, with several of these being significantly higher in more advanced stages of CRC. Stool fibrinogen, MMP-9, hemoglobin, MMP-8, and PGRP-S were the top 5 stool proteins with the highest accuracy for distinguishing advanced adenoma from HC, with stool fibrinogen topping the list with a receiver operating characteristic area under the curve value of 0.86. Functional pathway analysis revealed a significant over-representation of pathways related to antioxidant activity, integrin/receptor binding, cytokines, blood coagulation, and lipoprotein biosynthesis in patients with CRC compared with HC. Nuclear factor IC and IKZF2 were identified as key regulators of the molecular cascades over-represented in CRC. Stool fibrinogen, MMP-8, MMP-9, PGRP-S, haptoglobin, and myeloperoxidase emerge as promising biomarkers for distinguishing CRC/advanced adenomas/healthy stools, meeting or outperforming current yardsticks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.